Equities analysts expect that Wave Life Sciences Ltd (NASDAQ:WVE) will announce ($1.25) earnings per share for the current quarter, according to Zacks. Five analysts have issued estimates for Wave Life Sciences’ earnings, with estimates ranging from ($1.34) to ($1.05). Wave Life Sciences posted earnings of ($0.94) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 33%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 8th.
According to Zacks, analysts expect that Wave Life Sciences will report full-year earnings of ($4.99) per share for the current year, with EPS estimates ranging from ($5.21) to ($4.66). For the next year, analysts expect that the company will report earnings of ($2.88) per share, with EPS estimates ranging from ($5.03) to ($1.13). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Wave Life Sciences.
Wave Life Sciences (NASDAQ:WVE) last released its earnings results on Thursday, August 9th. The company reported ($1.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.88). The business had revenue of $4.88 million for the quarter, compared to analysts’ expectations of $7.38 million. Wave Life Sciences had a negative net margin of 1,473.26% and a negative return on equity of 91.88%.
Shares of Wave Life Sciences stock traded down $0.20 on Friday, hitting $48.69. 46,775 shares of the company’s stock traded hands, compared to its average volume of 170,487. The stock has a market cap of $1.47 billion, a P/E ratio of -12.30 and a beta of 1.00. The company has a current ratio of 6.11, a quick ratio of 6.11 and a debt-to-equity ratio of 0.05. Wave Life Sciences has a 52-week low of $21.20 and a 52-week high of $56.00.
In other Wave Life Sciences news, CFO Keith Regnante sold 29,500 shares of the stock in a transaction on Monday, September 24th. The stock was sold at an average price of $55.00, for a total value of $1,622,500.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Chandra Vargeese sold 3,000 shares of the stock in a transaction on Monday, September 24th. The stock was sold at an average price of $55.00, for a total value of $165,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,075 shares of company stock worth $2,435,700. Corporate insiders own 44.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Redmile Group LLC increased its position in Wave Life Sciences by 0.3% in the second quarter. Redmile Group LLC now owns 2,244,507 shares of the company’s stock worth $85,852,000 after buying an additional 6,900 shares during the period. Boxer Capital LLC increased its position in Wave Life Sciences by 17.8% in the second quarter. Boxer Capital LLC now owns 1,590,600 shares of the company’s stock worth $60,840,000 after buying an additional 240,600 shares during the period. Janus Henderson Group PLC increased its position in Wave Life Sciences by 11.8% in the second quarter. Janus Henderson Group PLC now owns 1,518,758 shares of the company’s stock worth $58,092,000 after buying an additional 160,545 shares during the period. BlackRock Inc. increased its holdings in shares of Wave Life Sciences by 37.0% during the second quarter. BlackRock Inc. now owns 1,201,655 shares of the company’s stock valued at $45,963,000 after purchasing an additional 324,659 shares during the period. Finally, BB Biotech AG increased its holdings in shares of Wave Life Sciences by 27.0% during the second quarter. BB Biotech AG now owns 1,137,885 shares of the company’s stock valued at $43,524,000 after purchasing an additional 241,789 shares during the period. 83.42% of the stock is currently owned by hedge funds and other institutional investors.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Featured Article: How can you know how many shares are floating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.